去氨加压素片及其注射液质量评价

doi:10.19803/j.1672-8629.20230385

中国药物警戒 ›› 2024, Vol. 21 ›› Issue (6): 632-637.
DOI: 10.19803/j.1672-8629.20230385

去氨加压素片及其注射液质量评价

孙悦, 胡馨月, 李晶, 张伟, 丁晓丽, 张慧^#, 梁成罡^*

中国食品药品检定研究院化学药品检定所,国家药品监督管理局化学药品质量研究与评价重点实验室,北京 102629

收稿日期:2023-06-21 出版日期:2024-06-15 发布日期:2024-06-18
通讯作者: ^*梁成罡,男,博士,研究员,激素及生物技术药物质量控制。E-mail：liangchenggang@nifdc.org.cn; ^#为共同通信作者。
作者简介:孙悦,女,硕士,助理研究员,激素类药物质量控制。
基金资助:
国家重点研发计划（2021YFF0600804）

Quality evaluation of desmopressin tablets and injection

SUN Yue, HU Xinyue, LI Jing, ZHANG Wei, DING Xiaoli, ZHANG Hui^#, LIANG Chenggang^*

Institute for Chemical Drug Control, National Institutes for Food and Drug Control, NMPA Key Laboratory for Quality Research and Evaluation of Chemical Drugs, Beijing 102629, China

Received:2023-06-21 Online:2024-06-15 Published:2024-06-18

摘要/Abstract

摘要： 目的对去氨加压素片及其注射液上市产品进行质量分析和评价,针对质量现状及存在问题展开探索性研究,为药品质量标准修订提供数据支持,为药品质控和监管提供参考。方法采用法定检验和探索性研究相结合的方式,对20批去氨加压素片和16批去氨加压素注射液进行全项检验,并开展片剂有关物质方法研究、片剂溶出度分析、片剂及注射液稳定性研究等探索性研究工作。结果 20批去氨加压素片和16批去氨加压素注射液法定检验合格率为100%。探索性研究对片剂有关物质测定方法进行了优化,消除了辅料聚维酮对检测的干扰;考察了国内外片剂产品溶出度,结果显示溶出行为相似;对片剂及注射液进行了稳定性考察,并对注射液中相关杂质进行了结构确证,主要为5位脱酰胺去氨加压素和光学异构体杂质。结论去氨加压素片及其注射液质量较好,质量标准需进一步完善。

关键词: 去氨加压素, 片剂, 注射液, 质量评价, 有关物质, 溶出度, 稳定性

Abstract: Objective To evaluate the quality of listed products of desmopressin tablets and its injection, and provide data for the revision of drug quality standards and for drug quality control and supervision. Methods Based on statutory inspection and exploratory research, 20 batches of desmopressin tablets and 16 batches of desmopressin injection were inspected before exploratory research was carried out, such as methodological research on related substances of tablets, dissolution analysis of tablets, stability of tablets and injections. Results The qualification rate of statutory inspection for 20 batches of desmopressin tablets and 16 batches of desmopressin injection was 100%. The exploratory research optimized the determination methods of related substances in tablets and the interference of the excipient povidone in detection was eliminated. The dissolution of tablets at home and abroad was investigated and the results showed that the dissolution behavior was similar. The stability of the tablets and injection was investigated, and the structure of impurities in the injection was confirmed, which were mainly 5-site deamidation desmopressin and optical isomer impurities. Conclusion The quality of desmopressin tablets and their injections is good, and there are still some problems with the quality standards, which need to be improved.

Key words: desmopressin, tablets, injection, quality evaluation, related substances, dissolution rate, stability

中图分类号:

R927.11

孙悦, 胡馨月, 李晶, 张伟, 丁晓丽, 张慧, 梁成罡. 去氨加压素片及其注射液质量评价[J]. 中国药物警戒, 2024, 21(6): 632-637.

SUN Yue, HU Xinyue, LI Jing, ZHANG Wei, DING Xiaoli, ZHANG Hui, LIANG Chenggang. Quality evaluation of desmopressin tablets and injection[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 632-637.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20230385

https://zgywjj.magtechjournal.com/CN/Y2024/V21/I6/632

参考文献

[1] WEISS JP, JUUL KV, WEIN AJ.Management of nocturia: the role of antidiuretic pharmacotherap[J]. Neurourol Urodyn, 2014, 33(S1): S19-24.
[2] FRIEDMAN FM, WEISS JP.Desmopressin in the treatment of nocturia: clinical evidence and experience[J]. Ther Adv Urol, 2013, 5(6): 310-317.
[3] GARONA J, PIFANO M, RIPOLL G, et al.Development and therapeutic potential of vasopressin synthetic analog [V4Q5] dDAVP as a novel anticancer agent[J]. Vitamins and Hormones, 2020, 113: 259-289.
[4] GASTHUYS E, DOSSCHE L, MICHELET R, et al.Pediatric pharmacology of desmopressin in children with enuresis: a comprehensive review[J].Pediatric Drugs, 2020, 22(8): 369-383.
[5] ZAORAL M, KOLC J, SORM F.Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-d-γ-aminobutyrine-vasopressin,1-deamino-8-d-lysine-vasopressin,and 1-deamino-8-d-argininevasopressin[J]. Collect Czech Chem Commun, 1967, 32(3): 1250-1257.
[6] WEISS JP, BLAIVAS JG, BLIWISE DL, et al.The evaluation and treatment of nocturia: a consensus statement[J]. BJU Int, 2011, 108(1): 6-21.
[7] ALFORD N, HASHIM H.Desmopressin acetate the first sublingual tablet to treat nocturia due to nocturnal polyuria[J]. Expert Review of Clinical Pharmacology, 2021,14(8): 939-954.
[8] NORGAARD JP, RITTIG S, DJURHUUS JC.Nocturnal enuresis: an approach to treatment based on pathogenesis[J]. Journal of Pediatrics, 1989, 114(4): 705-710.
[9] HJALMAS K, BENGTSSON B.Efficacy, safety, and dosing of desmopressin for nocturnal enuresis in Europe[J]. Clin Pediatr, 1993, 32(1_suppl): 19-24.
[10] MATTHIESEN TB, RITTIG S, DJURHUUS JC, et al.A dose titration, and an open 6-week efficacy and safety study of desmopressin tablets in the management of nocturnal enuresis[J]. Journal of Urology, 1994, 151(2): 460-463.
[11] VANDE WJ, METTE S, ANN R.Desmopressin 30 years in clinical use: a safety review[J]. Current Drug Safety, 2007, 2(3): 232-238.
[12] REMBRATT A, RIIS A, NORGAARD JP.Desmopressin treatment in nocturia; an analysis of risk factors for hyponatremia[J]. Neurourol Urodyn, 2006, 25(2): 105-109.
[13] WEATHERALL M.The risk of hyponatremia in older adults using desmopressin for nocturia: a systematic review and meta-analysis[J]. Neurourol Urodyn, 2004, 23(4): 302-305.
[14] HU CQ,PAN RX.Progress in evaluation /prediction of bioequivalence of solid oral preparations by dissolution test[J]. Chinese Journal of New Drugs(中国新药杂志), 2014, 23(1): 44-51.
[15] National Medical Products Administration.Technical guidelines for dissolution tests of ordinary oral Solid dosage forms[EB/OL]. (2015-02-05)[2015-02-05]. https://www.nmpa.gov.cn/directory/web/nmpa /xxgk/ggtg/qtggtg/20150205120001100.html.

去氨加压素片及其注射液质量评价

Quality evaluation of desmopressin tablets and injection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	魏曼莉, 吕林艳, 郑志远, 尹纪业, 麦志雄. 血栓通注射液临床前遗传毒性研究[J]. 中国药物警戒, 2024, 21(9): 1014-1018.
[2]	刘婷, 曹忠强, 何文佳, 袁秀丽, 陈泽彬, 李学娟. 培门冬酶注射液致急性重症胰腺炎1例分析[J]. 中国药物警戒, 2024, 21(9): 1075-1077.
[3]	刘毅, 刘晓强, 姚晓, 李选堂, 郭贤辉, 耿颖, 裴宇盛. 溴己新注射剂临床配伍用药研究[J]. 中国药物警戒, 2024, 21(8): 884-887.
[4]	孙莉, 谢彬, 徐艳琴. 中药缓控释制剂研究进展[J]. 中国药物警戒, 2024, 21(8): 949-954.
[5]	丁晓丽, 胡馨月, 王雪蕾, 孙悦, 李晶, 张慧, 梁成罡, 王岩. 甘精胰岛素注射液质量状况评价与研究[J]. 中国药物警戒, 2024, 21(6): 644-650.
[6]	刘毅, 覃玲, 郭贤辉, 陈华, 裴宇盛. 热重和差示扫描量热分析技术在药物分析中的应用进展[J]. 中国药物警戒, 2024, 21(3): 283-289.
[7]	陈杰, 张斌, 赵俊, 张传洲. 托珠单抗注射液致过敏性休克1例分析[J]. 中国药物警戒, 2024, 21(3): 349-351.
[8]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[9]	江楠, 王琨, 张钢平, 邢瑞敏, 王海叶. 异甘草酸镁注射液致过敏性休克1例分析[J]. 中国药物警戒, 2024, 21(11): 1309-1311.
[10]	李耀磊, 金红宇, 魏锋, 马双成. 前胡的一般概况及质量形成因素浅析[J]. 中国药物警戒, 2024, 21(11): 1315-1320.
[11]	巨康璐, 常瑛, 刘振国. 缩宫素注射液致严重过敏样反应1例分析[J]. 中国药物警戒, 2024, 21(10): 1169-1171.
[12]	刘猛, 方可, 严家菊, 刘梦, 何曼云, 魏良兵. 帕米膦酸二钠葡萄糖注射液致过敏性休克 1 例分析[J]. 中国药物警戒, 2024, 21(10): 1172-1174.
[13]	史卜文, 李利寻, 谢雁鸣, 王志飞, 王淇. 真实世界喜炎平注射液治疗3846例细菌性肠道感染患者临床用药特征分析[J]. 中国药物警戒, 2023, 20(9): 1017-1021.
[14]	傅孟君, 姚慧慧, 朱克旭, 王馨远, 姚尚辰. 吲达帕胺片仿制药及其参比制剂溶出曲线比对评价研究[J]. 中国药物警戒, 2023, 20(7): 763-768.
[15]	孟康康, 刘赛月. 辅酶Q10注射剂上市后安全性分析[J]. 中国药物警戒, 2023, 20(7): 795-798.